SCHEMBL3402925

SCHEMBL3402925

NCc1cc2cc(Cl)ccc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.58
LOXL2 Q9Y4K0 3/20 0.58
ASIC3 Q9UHC3 1/20 0.58
AKR1B1 P15121 1/20 0.39
IDO1 P14902 1/20 0.39
AGXT P21549 1/20 0.37
PNMT P11086 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CA2 P00918 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
ALOX12 P18054 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29792534 0.85 CYP2A6 (0.58) CYP2A6LOXL2ASIC3IDO1AGXT
SCHEMBL17253661 0.85 CYP2A6 (0.58) CYP2A6LOXL2ASIC3IDO1AGXT
SCHEMBL2080656 0.82 AKR1B1 (0.40) CYP2A6LOXL2ASIC3AKR1B1IDO1
SCHEMBL2090663 0.81 CYP2A6 (0.40) CYP2A6LOXL2ASIC3AKR1B1IDO1
SCHEMBL424764 0.81 AKR1B1 (0.39) CYP2A6LOXL2ASIC3AKR1B1IDO1
SCHEMBL2094705 0.81 AKR1B1 (0.41) CYP2A6LOXL2ASIC3AKR1B1IDO1
SCHEMBL2056139 0.81 AKR1B1 (0.39) CYP2A6LOXL2ASIC3AKR1B1IDO1
SCHEMBL11485426 0.81 CYP2A6 (0.58) CYP2A6LOXL2ASIC3AKR1B1IDO1
SCHEMBL2039262 0.78 CYP2A6 (0.42) CYP2A6LOXL2ASIC3AKR1B1IDO1
SCHEMBL16414423 0.78 AKR1B1 (0.38) CYP2A6LOXL2ASIC3AKR1B1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3027615-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2021-07-21 EP disclosed
US-20160185774-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2016-06-30 US disclosed
US-20160185774-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2016-06-30 US disclosed
WO-2015014993-A2 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2015-02-05 WO disclosed
US-8470859-B2 Iminopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-25 US disclosed
US-8470859-B2 Iminopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-25 US disclosed
EP-2252590-A1 SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS BASF SE (DE) 2010-11-24 EP disclosed
US-20100016315-A1 Iminopyridine Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
US-20100016315-A1 Iminopyridine Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
WO-2009101082-A1 SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS BASF SE (DE) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016315-A1 Iminopyridine Derivative and Use Thereof ADRA1D, ADRB1, ADRB2 CYP2A6 3045/4885LOXL2 2234/4885ASIC3 2634/4885
US-20160185774-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 CYP2A6 3389/4885LOXL2 3227/4885ASIC3 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.